Table 1.

Trials with immune checkpoint inhibitors in metastatic Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC)

Merkel cell carcinoma	ORR (95% CI)	1 year OS	ESMO-MCBS
Avelumab (anti-PD-L1)
First-line treatment (n = 29)	62% (42–79)	Data not available	3
Second-line treatment for metastatic MCC (n = 88)	33% (23–44)	52%	3
Pembrolizumab (anti-PD-1)
First-line treatment for recurrent locally advanced or metastatic MCC (n = 50)	56% (35–76)	72%	3
Cutaneous squamous cell carcinoma	ORR (95% CI)	1 year OS	ESMO-MCBS
Cemiplimab (anti-PD-1)
First- or second-line treatment for metastatic cSCC (n = 59)	47% (34–61)	Data not available	3

The ESMO-Magnitude of Clinical Benefit Scale Version 1.1 (ESMO-MCBS) is a tool for evaluation of the magnitude of benefit from clinical studies [21]. The maximum score for a single-arm study is 4 and can only be achieved when quality-of-life data are available.

ORR, objective response rate; CI, confidence interval; OS, overall survival; PD-L1, programmed death ligand 1; PD-1, programmed death 1.